Leishmaniasis is a neglected tropical disease responsible for the ninth largest disease burden in the world threatening 350 million people mostly in developing countries. The lack of efficacy, severe adverse effects, long duration, high cost and parenteral administration of the current therapies result in poor patient compliance and emergence of resistance. Leishmaniasis' unmet need for safer, affordable and more effective treatments is only partly addressed by today's global health product pipeline that focuses on products amenable to rapid clinical development, mainly by reformulating or repurposing existing drugs for new uses. Excipients are necessary for ensuring the stability and bioavailability of currently available antileishmaniasis drugs which in their majority are poorly soluble or have severe side-effects. Thus, selection of excipients that can ensure bioavailability and safety as well as elicit a synergistic effect against the Leishmania parasites without compromising safety will result in a more efficacious, safe and fast to market medicine. We have evaluated the in vitro activity of 30 commercially available generally regarded as safe (GRAS) excipients against different Leishmania spp., their cytotoxicity and potential use for inclusion in novel formulations. Amongst the tested excipients, the compounds with higher selectivity index were Eudragit E100 (cationic triblock copolymer of dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate), CTAB (cetyltrimethylammonium bromide, cationic), lauric acid, Labrasol (non-ionic, caprylocaproyl polyoxyl-8 glycerides) and sodium deoxycholate. An ideal excipient need to possess amphiphilic nature with ionic/polar groups and possess a short or medium fatty acid chain such as lauric (C12), capric (C10) or caprylic acid (C8). Inclusion of these excipients and identification of the optimal combination of drug and excipients would lead to a more effective and safer antileishmanial therapies.
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Introduction
Leishmaniasis is a neglected tropical disease responsible for the ninth largest disease burden [1] . Currently, leishmaniasis threatens 350 million men, women and children in 88 endemic areas around the world, 72 of which are developing countries with limited healthcare budgets [2] . The three major manifestations of the disease are: visceral (VL), cutaneous (CL) and mucocutaneous (MCL) leishmaniasis. CL new cases are estimated to range from 0.7 to 1.3 million while VL new cases range between 0.2 to 0.4 million according to the World Health Organisation (WHO) [3] . Patients illustrate clinical symptoms ranging from simple cutaneous lesions to mucocutaneous ulcers or systemic disease affecting vital body organs such as the liver and spleen or show a confounded severe clinical manifestation complicated by other coinfections such as HIV/AIDS [4] . The fatality rate of VL can be as high as 100% within two years if left untreated and the disease is characterised by fever, weight loss, anaemia and swelling of the spleen and liver (where parasites are located in high amounts and replicate) [2] .
Although fatality rate of CL or MCL is lower compared to VL, the skin and mucous membrane lesions are debilitating resulting in serious disability and stigma leaving patients permanently scarred, unable to be employed and sometimes casted out from society [2, 3] .
The therapeutic arsenal to treat leishmaniasis is far from ideal. Pentavalent antimonials including sodium stibogluconate (SSG) and N-methylglucamine antimoniate (meglumine antimoniate) remain the first line treatment for VL (Table 1 ) [5] . As resistance to antimonials is becoming more common limiting their use, emerging second-line treatments involve pentamidine and Amphotericin B (AmB). AmB administered parenterally is highly effective in VL and is available as an affordable micellar formulation (Fungizone ® ) which is highly nephrotoxic limiting the dose able to be administered [6] , a liposomal formulation Cost of therapy with AmB is also further increased by the need for cold transport and refrigeration. This has led to the clinical use of heated Fungizone ® in India (prepared by 10- fold dilution with water and heating to 70 o C for 20 minutes [7] ) which results in larger AmB aggregates that are not cleared by the kidneys effectively reducing observed nephrotoxicity [8] .
Pentamidine, another second-line drug, has been shown to cause insulin dependent diabetes which is irreversible and potentially fatal [8] .
Although many research efforts are focused on developing an oral amphotericin B formulation, no oral formulations are currently marketed due to its poor aqueous solubility and permeability across biological barriers [6, 9, 10] . Other clinically used medicines for leishmaniasis include paromomycin (characterised by its low cost but variable efficacy) and miltefosine. The latter, which was first licensed in India in 2003 as the first oral licensed treatment, possesses a long elimination half-life (7 days) and a narrow therapeutic index limiting the dose administered allowing for subtherapeutic levels to remain for several weeks encouraging the emergence of resistance [11] . This has already been observed in India (Bihar region that accounts alone for 50% of VL worldwide burden) and France [12] . Miltefosine has also known teratogenic effects which limits its use in women of child-bearing age and pregnant women [13] .
As there is no effective vaccine for any of the ten WHO identified neglected tropical diseases including Leishmania, there is an unmet need for enhancing the efficacy, safety, compliance and affordability of available therapies as well a need to develop new medicines. To achieve this, ideally new chemical entities (NCEs) are required with enhanced potency, specificity, and lack of toxicity in order to provide breakthrough therapeutic benefits within a wide safety margin. However, they are riskier to invent than expanding the use of existing drugs by either repurposing or reformulating them or by combining them in novel fixed-dose combinations with enhanced efficacy and reduced duration of treatment.
Excipients are components of a finished drug product other than the active pharmaceutical ingredient (API) and are added during formulation for well-defined functions that can vary from facilitating the manufacture process (such as diluents, binders, lubricants), protecting the drug from physicochemical degradation (stabilisers, antioxidants), improving the bioavailability of the API (solubility and permeability across biological membranes, targeting, controlled-release). However, excipients could potentially work synergistically with the API resulting in an enhanced overall efficacy and safety of the medicine. In this study, we explore this hypothesis by assessing the in vitro activity against Leishmania spp. of 30 commercially available excipients and their cytotoxicity in order to evaluate their potential for inclusion in novel engineered dosage forms against leishmaniasis. Table 2 were prepared and characterised by Dr Aikaterini Lalatsa (University of Portsmouth, Portsmouth, UK) using previously published methods [14] .
Materials and methods

Materials
Cell culture media and all other chemicals (>98%) were purchased without further purification from Sigma-Aldrich (Dorset, UK).
Methods
The selected excipients were classified into the following categories according to their brasilensis and L. amazonensis) and also as they have shown a variable in vitro susceptibility to drugs in previous studies (L. brasiliensis was more susceptible than L. amazonensis) [16] .
Promastigotes were cultured in Schneider's Insect medium supplemented with 10% heatinactivated foetal bovine serum (FBS, Sigma-Aldrich) and 1000 U/L of penicillin plus 100 mg/L of streptomycin in 25 mL culture flasks at 26 °C [17] .
In vitro promastigote susceptibility assays
The in vitro activity studies were performed as previously described [18, 19] . Briefly, logphase promastigotes (2.5 x 10 5 parasites/well) were cultured in 96-well plastic plates. All excipients were dissolved in 0.22µm filtered water at 100 mg/ml concentration except from those with poor solubility in water that were dissolved at 100 mg/ml using either in DMSO (for all the lipids, phospholipids, cholesterol and α-tocopherol) or in DCM (for both methacrylate polymers). In addition, amphiphiles were probe sonicated for 15 min to ensure complete dispersion in deionised water. Further dilutions of the excipients using the above described medium were performed and were added up to 200 µL final volume resulting in a final concentration of 200, 100, 50, 25, 12.5, 6.25 3.125 and 1.065 μg/ml per well. Growth controls were also included. The final solvent (DMSO or DCM) concentrations never exceeded 0.5%
(v/v) warranting no effect on parasites proliferation or morphology [20] . Growth inhibition (%) = 100 − RFU treated wells -RFU signal to noise RFU untreated -RFU signal to noise 100 Eq. 1
All tests were carried out in triplicate. Miltefosine (≥98%, HPLC) dissolved in DMSO was used as the reference drug. The efficacy of each compound was estimated by calculating the IC50 (concentration of the compound that produced a 50% reduction in parasites) and GI% (percentage of growth inhibition at 200 µg/ml).
Cytotoxicity studies on murine macrophages
Cytotoxicity tests were performed only for those excipients that possessed in vitro micromolar activity against promastigotes. As previously described, J774 murine macrophages were grown in RPMI 1640 medium supplemented with 10% heat-inactivated FBS (30 min at 56 °C), penicillin G (100 U/mL) and streptomycin (100 μg/mL) [17] . For the experiments, cells in the pre-confluence phase were harvested with 0.03% EDTA-0.05% Trypsin in PBS for 20 minutes.
Cell cultures were maintained at 37 °C in a humidified environment with 5% CO2 (HucoaErlöss, Forma Scientific, Ohio, USA).
The assay was carried out as previously described [16] . J774 macrophages cell lines were seeded (5 × 10 4 cells/well) in 96-well flat-bottom microplates with 100 μL of RPMI 1640 medium. The cells were allowed to attach for 24 h at 37 °C, 5% CO2, and the medium was replaced by different concentrations of the compounds resulting in 200 μL volume with a final concentration identical to the one above described. Macrophages were exposed to the excipients for 24 h. Growth controls were also included. Afterwards, a volume of 20 μL the 2.5 mM resazurin solution was added, and plates were incubated for another 3 h to evaluate cell viability. Eq. 2
Results and Discussion
Selected excipients commonly used in the development of drug formulations and nanomedicines were evaluated for their in vitro efficacy against promastigotes of VL and CL causing Leishmania spp. with different susceptibility against common antileishmanial drugs [21] . Among the selected excipients, the compounds that exhibited the lowest IC50 against L.
amazonensis were as follows: Eudragit E100 < CTAB < DOTAP-CL < sodium deoxycholate ~ lauric acid < Labrasol. L. braziliensis and L. donovani was found to be more susceptible to excipients than L. amazonensis resulting in lower IC50 for tested compounds. The in vitro activity of the excipients against L. braziliensis ranked as follows: Eudragit E100 < CTAB < lauric acid < Solutol HS15 < Labrasol < sodium deoxycholate < DOTAP-CL < Tween 20. The order of excipients with activity against L donovani follows a similar order to that of L amazonensis with the exception of DOTAP-CL that showed no activity at the tested concentration and lauric acid that illustrated a higher IC50 (Eudragit E100 < CTAB < sodium deoxycholate < Labrasol < Tween 20 < Solutol HS15 < lauric acid) ( Table 5 ). The excipients illustrating the least cytotoxicity but the higher CC50 values were: stearic acid and Eudragit E100 (which showed very limited cytotoxicity at the highest tested concentration) followed by (Table 5) , this is not surprisingly. However, previous studies have also illustrated the efficacy of cationic stearylamine-bearing liposomes against L. donovani by interaction with the surface exposed negatively charged phosphatidylserine on leishmania parasites abundant in parasitic cell membranes but not in mammalian cells [23] [24] [25] .
DOTAP-CL, a cationic phospholipid quaternary ammonium chloride salt, needed higher concentrations to elicit a 50% reduction in Leishmania promastigotes in L. braziliensis and L.
donovani. However, for a cationic and quaternary ammonium amphiphile as CTAB the reverse trend was observed. The presence of a quaternary ammonium moiety ionised in physiological pH as observed within CTAB and DOTAP-CL as well the orally bioavailable miltefosine has been implicated for efficacy against Leishmania and Plasmodium protozoa [22] . Although the specific mechanism of action of miltefosine against Leishmania spp. is not fully understood, the mode of action of this drug is likely to be very similar as its mechanism of action against human cancer cells linking its activity mainly to apoptosis (producing reactive oxygen species resulting in DNA fragmentation, nuclear condensation and loss of cell volume), but also disturbance of membrane lipids (inhibition of phosphatidylcholine and sphingomyelin biosynthesis and ether-lipid metabolism) and inhibition of cythochrome c oxidase [26] [27] [28] . The difference in activity between DOTAP-CL and CTAB can also be explained by the fact that quaternary ammonium bromides have been shown to be more active against parasites compared to quaternary ammonium chloride salts [22, 29] . Activity of quaternary ammonium compounds can be related with its ability to inhibit water permeation through aquaporins which leads to cell death [30] . Thus, DOTAP-CL will need to be present in high amounts in liposomes or bilosomes for an antileishmanial dosage form if at all useful for a VL medicine [31] .
Ionic surfactants cause disruption of the cell membrane integrity with cationic surfactants being the most cytotoxic followed by anionic and then non-ionic surfactants [32] . This is supported by the higher CC50 value of sodium deoxycholate compared to cationic CTAB and DOTAP-CL [33] , as cationic surfactants are known to promote destabilisation of DNA [33] . Anionic amphiphiles such as sodium deoxycholate have also shown activity against Leishmania protozoa ( [35] and a polyoxyethylene glycol derivative of steraric acid (MYRJ 59) [36] , although interaction of amphotericin B with laurylsucrose was stronger than that of sodium deoxycholate [37] . Both sodium deoxycholate and laurylsucrose enhance the selectivity of the AmB binding to sterols at exactly the concentrations of the surfactants which induce the monomerization of the antibiotic, while the maximal selectivity was found at a concentration of the surfactants corresponding to their particular CMC in presence of amphotericin B [35] .
Our study is one of the first systematic studies to report on the antileishmanial activity of short and medium chain saturated fatty acids. The high reported activity of lauric acid and Labrasol against Leishmania parasites can be attributed to their ability to selective permeabilise the cell membrane resulting in a rapid and considerable membrane damage and a loss of cellular potassium and magnesium [38, 39] . The toxicity of short chain fatty acids that affects both membrane fluidity and integrity has been previously reported on certain bacteria like E. coli and C. resinae but not against Leishmania spp [38, 39] . The rate and extent of the ion efflux is dependent on the chain length of the compounds [38, 39] . Short fatty acid chains mainly in their un-dissociated form are more soluble in water that longer chains which are more flexible and are able to permeate easier in higher concentrations in the cytoplasmic membrane and cause the disorientation of essential membrane components [38] . Also, similar effects on the intracellular membrane systems may account for the inhibition of endogenous respiration [38] .
Similar to our study, lauric acid has previously illustrated dose-dependent inhibition of L.
infantum, however a comparison with other fatty acids was not available [40] . Similarly, Labrasol (a mixed ester of capric and caprylic acid) also illustrated a high antileishmanial activity in the nanomolar range, even though Labrasol lacks a clear ionic nature due to the shielding effect provided by the polyethylene glycol (PEG) chains and possesses a larger hydrophilic head group than lauric acid [41] . It is important to note, that caprylic and capric acids are medium-chain saturated fatty acids that account for 65% and 35% of the composition of medium-chain triglycerides, which are the sources of abundant and rapidly available energy in the Leishmania parasite [42] especially in the stationary phases of the Leishmania spp.
Longer chain lipids (stearic acid, tripalmitin), lipid esters (Labrafil) and anionic phospholipids (Soy Phosphatidylcholine, Lipoid S100) at tested concentrations did not show activity.
Short-chain triglycerides (C8) have been reported to exhibit high antimicrobial activity against
Gram-positive and Gram-negative bacteria which was greater than octanoic acid [43] , thus commonly using these triglycerides as food preservatives. Better incorporation within the cell membrane and the ability to form transient or permanent pores in the membrane or even solubilise membranes was reported as possible explanations for this [43, 44] . However, there is a large variation in susceptibility among different species of bacteria which can be explained by the fact that monocaprylate only integrates in specific regions of the membrane (Ld phase) depending on membrane fluidity and phospholipid composition [43] . Lipid phase coexistence (mainly Ld, liquid disordered phase and Lo, liquid ordered phase characterised by substantial amounts of cholesterol) is a phenomenon of potential biological significance [45, 46] . The phase boundaries play a key role in membrane permeabilisation. The interface between two lipid phases has a line tension inducing packing defects at the hydrophobic interface of the lipid phase and thus, these defects increase membrane permeability [43, 47] . Lipid derivates are found to partition strongly into the Ld phases whereas polycyclic aromatic hydrocarbons with a flat ring partition preferentially into Lo phases [45] . Lipophosphoglycan (LPG) is one of the dominant surface macromolecules of the promastigote stage of all Leishmania parasitic species. LPG structural polymorphism has a significant impact on parasite survival but also in infectivity both in the sandfly vector and the mammalian host [48] . Monocaprylate can incorporate into the Ld phase of the membrane allowing to become more hydrated and thus increasing its permeabilisation [43] . The different abilities of monocaprylate to intercalate within the cellular membrane can partly explain the observed variability in the in vitro activity of lauric acid and Labrasol against all Leishmania spp.
In addition, short and medium chain fatty acids do not only possess a direct antileishmanial activity, but can also modulate the efficacy of other antileishmanial drugs altering the binding of the drugs with the sterols of the protozoa membrane. One of the major limitations of amphotericin B is a direct result of the binding of the drug to both cholesterol of mammalian cells as well as ergosterol of the fungal cells leading to death cell [49] . Some surfactants such as sucrose monolaurate have been previously shown to selectively decrease the binding of the amphotericin B to cholesterol without interfering with its binding to ergosterol reducing its toxicity and consequently, enhancing its therapeutic index [50] . However, in our study we have not tested this. AmB formulation. The latter formulations are increasingly receiving interest due to their costeffective ease of manufacture and scalability, ability to be converted from a colloidal into a solid dosage form with enhanced oral permeability and thermal stability [54] . Short and medium chain fatty acids as excipients are increasingly included within formulations of poorly soluble as well as peptide/protein drugs to increase their oral bioavailability [55] [56] [57] [58] [59] , as well their capacity to inhibit the P-glycloprotein in the intestine which limits the oral bioavailability of many drugs [60] .
Non-ionic surfactants
Additionally, it is generally suggested that the C12 and C14 hydrophobic chains have an optimal balance of partition co-efficient and affinity for the skin [61] [62] [63] , with the permeation enhancing effects for saturated fatty acids sharply increasing up to 11 carbons and reducing with increasing chain length [64, 65] . In addition, ionic surfactants are good permeation enhancers across the stratum corneum layer which facilitates the accessibility of the drug to the parasite foci commonly located at the dermis level [66] . Thus, an ideal excipient for both oral and transcutaneous administration needs to be an amphiphile of a short or medium fatty acid chains (such as lauric (C12), capric (C10) or caprylic acid (C8) or their esters) with a polar head group that is ideally charged (such as a quaternary ammonium group). Our recent results as well as our previous in vitro and in vivo studies using a novel chitin derived pharmaceutical amphiphile (N-palmitoyl-N-monomethyl-N,Ndimethyl-N,N,N-trimethyl-6-O-glycolchitosan (quaternary ammonium palmitoyl glycol chitosan-GCPQ) support this [9] .
Conclusions
Excipients are used for many different purposes in formulations such as API stabilisation, Table 5 . Leishmanicidal activity of selected excipients on extracellular forms (L. amazonensis, L. braziliensis and L. donovani) and cytotoxicity on J774 macrophages. Cytotoxicity on macrophages was only determined for those excipients that showed activity against Leishmania parasites. Key: NA, non-active at the highest tested concentration (200 µg/ml); NC, non-cytotoxic at the highest tested concentration (200 µg/ml); IC50, concentration of the excipient that produced a 50% reduction in parasites; CC50, concentration of the excipient that produced a 50% reduction of cell viability in treated culture cells with respect to untreated ones; GI(%), percentage of inhibition at the highest tested concentration (200 µg/ml); SI, selectivity index calculated as CC50/IC50; MW, molecular weight; GC, glycol chitosan. Molecular weight of Labrasol was calculated based on the specification of the US Pharmacopeia where it is stated that the mean relative molecular weight is between 200 and 400 g/mol [97] . The calculated molecular weight of Solutol HS15 was 655.7 g/mol which cobtained taking into account 30% of free polyethylene glycol 660 (MW= 660 g/mol) and 70% of an equal mixture of polyglycols of mono-and di-esters of 12-hydroxystearic acid (MW= 644.5 and 963.2 g/mol). 
